Now I have all the information I need. Let me write the consolidated review.

## Summary

This paper proposes SimBOL, a framework for localizing the site of origin (SoO) of early ventricular activation from 12-lead ECGs. The method combines an onset-based data augmentation strategy (which resamples within a window anchored to the QRS onset to generate additional training samples) with a compact 1D CNN architecture designed to balance between limited clinical data and model complexity. SimBOL achieves a mean localization error of ~9.83 mm (below the 10 mm clinical threshold) on a dataset of 1,012 LV pacing sites, and ablation studies with Transformer variants support the data-parameters balancing thesis.

## Strengths

- **Well-motivated onset-based data augmentation with clear ablation support**: The augmentation strategy is grounded in the physical structure of ECG signals (resampling within an onset-defined window). Table 1 provides a clean ablation showing that ODA alone improves mean error from 12.94 mm (×1) to 9.88 mm (×5), while additional traditional augmentations (noise, amplitude scaling, baseline wander) add little value at higher resampling rates. This directly substantiates the claim that the augmentation, rather than other factors, drives the improvement.

- **Transformer ablation directly supports the data-parameters balancing thesis**: Figure 9 shows that adding a Transformer block (T+SimBOL) requires ×15 resampling to stabilize, while the smaller SimBOL stabilizes at ×5. The two models converge to similar final errors (~9.78 vs 9.83 mm), but the smaller model reaches stability with far less data. This is the cleanest evidence for the paper's central argument and is a well-designed experiment.

- **Detailed anatomical error analysis**: Figure 7 and Section 5.3.2 identify segments 7, 8, 9, and 14 as problematic due to septal anatomy, papillary muscles, and data sparsity. This provides actionable insight for future work on finer-grained localization in clinically difficult regions. The analysis is candid about where the method fails, which strengthens credibility.

- **Reproducible experimental setup with variance reporting**: The paper runs each experiment five times with different seeds and reports mean ± variance (Table 1). SimBOL variances are modest (0.18–0.28 mm), suggesting stable optimization.

## Weaknesses

### Major

- **Uncontrolled baseline comparison undermines the "outperforming" claim**: The baselines (QRSI at 15.09 mm, CNN at 14.02 mm, f-SAE(GRU) at 12.84 mm, SVR at 11.80 mm) are presented as single point estimates without variance, and the paper never states that these methods were re-implemented and evaluated under the same data split, preprocessing, and evaluation protocol as SimBOL. The language describing them ("The SVR model Zhou et al. (2019) is a linear regression model based on 120-ms QRS-integrals. It achieved an average localization accuracy of 11.80 mm") indicates these are published results from prior papers rather than controlled re-runs. Since the data split methodology (Section 5.2.1) is specific to this paper (placing single-sample labels only in training), the test sets are likely different. Without a controlled head-to-head comparison, the 2 mm improvement over SVR cannot be confidently attributed to the method. This is the paper's most significant weakness, as outperforming existing methods is a central claim in the abstract, introduction, and conclusion.

### Minor

- **Single-dataset evaluation limits generalization evidence**: All experiments use one dataset of 1,012 LV pacing sites from Sapp et al. (2017) based on a single generic LV model. The paper acknowledges that 25 of 238 triangle labels have no samples and 27 have only one sample, but does not evaluate on an independent cohort. The segment-level analysis already reveals unstable performance in septal/papillary regions (segments 7, 8, 9, 14), suggesting brittleness in precisely the areas where clinical need is highest. While single-dataset studies are common in this clinical niche, this limits the strength of the generalization claims.

- **Parameter counts are not reported**: The paper's central thesis is that balancing data and parameters mitigates overfitting, yet it never states the total parameter count for SimBOL or any baseline. While the architecture description (conv layers with 256 and 25 channels, one FC layer) allows approximate estimation, explicit counts would directly substantiate the "small-scale" narrative and enable readers to assess the claimed data-parameter balance quantitatively.

- **Test set evaluation treats resamples as independent**: Each of the 231 test samples is resampled 10×, producing 2,310 test predictions that are then treated as independent for computing mean error. Multiple predictions from the same original ECG are not independent, which likely underestimates variance and may bias the reported accuracy. Per-site averaging (one error per original pacing site, averaged across resamples) would be more appropriate.

- **Single-sample triangle labels placed exclusively in training**: Section 5.2.1 puts labels with only one sample entirely in the training set. This means the test set excludes these rare locations, potentially inflating reported performance since the model is never evaluated on the hardest-to-generalize sites. A location-aware evaluation or explicit discussion of this limitation is needed.

- **Onset-based augmentation lacks clinical validation**: The augmentation fills "any portion of P that is not captured within the sample" with "adjacent QT interval data," potentially mixing temporally disjoint signal segments. While the method is clearly described (Section 4.1, Figure 4) and the ablation shows it works, there are no visual examples of augmented samples or physician assessment of clinical plausibility. This is a validation gap rather than a fatal flaw, but it would strengthen the paper.

### Trivial

- None beyond standard formatting artifacts (parser-inserted line numbers, minor notation preferences).

## Nice-to-Haves

- A model depth/width sweep (e.g., varying number of conv blocks or channels) with and without augmentation would directly test the claim that smaller models are preferable for this data regime.
- Discussion of how onset detection reliability affects the augmentation, since the paper acknowledges that accurate QRS onset identification in ventricular arrhythmias is challenging.
- Per-site error reporting (averaging resamples per original site) rather than treating 2,310 resampled test predictions as independent samples.

## Removed Points

*These points were identified in the inputs but removed after verification against the paper:*

- "7x7 conv1d notation is 2D notation applied to 1D convolutions" — This is a formatting/notation nitpick from the PDF parser; the description is clear in context.
- "Relu typo" — A formatting artifact from PDF extraction; the original submission does not have this issue.
- "Input length L=800 not justified" — The paper states it is "based on actual clinical ECGs" which is reasonable given the 1 kHz sampling rate and QT interval duration.
- "Section 2.2 (ECG vs. speech) is tangential" — A scope judgment, not a concrete weakness. The section contextualizes why speech-domain models should not be naively applied.
- "SimBOL ×1 is worse than SVR" — This is a factual observation from the data, not a weakness of the method; it shows augmentation is necessary.
- "ODA alone vs ODA+others shows no clear winner" — This is a finding, not a weakness; the paper correctly interprets it.
- "Transformer ablation difference is only 0.05 mm" — The paper's claim is about *stabilization rate* (×5 vs ×15), not final error. The interpretation is accurate.
- "Conclusion overstates contributions" — This is an opinion not tied to a specific factual error.
- "No depth/width ablation" — Moved to Nice-to-Haves; it would strengthen but is not a core flaw.
- "Onset detection reliability not discussed" — Moved to Nice-to-Haves; the paper acknowledges the challenge of onset detection in arrhythmias.
- "Section 2.2 removed without weakening" — Scope judgment; not a concrete weakness.

## Novel Insights

None beyond the paper's own contributions. The key insight — that a simple data-parameter balancing framework with onset-based augmentation outperforms more complex models in a low-data ECG localization task — is well-articulated by the authors themselves. The reviewers' perspectives did not surface a genuinely novel observation that the paper missed.

## Suggestions

1. **Re-run baselines under identical conditions**: Re-implement QRSI, CNN, f-SAE(GRU), and SVR using the same train/test split (Section 5.2.1) and evaluation protocol, and report their performance with variance across seeds. This is the single most impactful change to substantiate the "outperforming" claim.

2. **Report parameter counts**: Add a table listing total trainable parameters for SimBOL, T+SimBOL, SimBOL+T, and all baselines. This directly supports the data-parameters balancing narrative.

3. **Use per-site averaging for test evaluation**: Compute one mean error per original pacing site (averaging across the 10 resamples), then report statistics over the 231 sites. This removes the artificial statistical dependence from treating resamples as independent.

4. **Add visual examples of augmented signals**: Show a few examples comparing original and ODA-augmented samples, ideally with annotations highlighting how the resampling window and "adjacent QT interval" fill-in affect signal morphology.

5. **Discuss the impact of single-sample labels in training**: Acknowledge that test set performance excludes the hardest-to-generalize locations and discuss how this might affect the reported accuracy.

## Score and Decision

**Calibration anchors:**

| Path | Avg Score | Round | Comparison to this paper |
|------|-----------|-------|------------------------|
| olnuBGxGRs.md | 1.00 | R1 | Much weaker — narrow scope, poor evaluation |
| 7zJDTnogdG.md | 3.33 | R1 | Similar area but weaker experimental grounding |
| QjrC77Nyu6.md | 2.50 | R1 | Weaker — limited empirical validation |
| v3XabZsB7j.md | 2.00 | R1 | Much weaker — trivial contribution |
| 66j2BdZv07.md | 3.75 | R1 | Weaker — missing comparisons, unclear benefits |
| NOfmlsnCsS.md | 5.50 | R1/R2 | Slightly stronger in scope/scale but had comparison fairness issues |
| 6kjTRMJ3be.md | 4.50 | R2 | Similar — good motivation, single-dataset concerns |
| vFfVXSP24J.md | 5.50 | R2 | Stronger benchmark contribution but mixed reviews |
| DUsSJcq4Nz.md | 3.00 | R1 | Weaker — narrow scope, poor presentation |
| QNW42cjkym.md | 3.50 | R2 | Weaker — insufficient novelty |
| nk8HrBad2O.md | 5.00 | R2 | Similar — point-localization task, comparable rigor |
| 7ut8T9iJ7P.md | 4.50 | R2 | Comparable — solid but not exceptional |

**Round 1 bracket**: Between approximately 3.5 and 7.5. The paper is clearly stronger than the 1.0–3.33 papers but does not reach the quality of the 8+ papers.

**Round 2 narrowing**: The paper is most comparable to the 4.5–5.5 anchors (ZODIAC avg 4.5, MEIT avg 5.5, point localization avg 5.0). It has a cleaner, more focused experimental design than ZODIAC but a more modest contribution scope than MEIT. The uncontrolled baseline comparison is a significant weakness that prevents it from reaching the 5.5–6 level.

**Final**: This is a solid paper with a well-motivated method and informative internal ablation studies. However, the uncontrolled baseline comparison undermines the central "outperforming" claim. The score reflects a paper with meaningful technical contribution that needs to address the comparison fairness issue before the performance claims can be taken at face value.

MY FINAL SCORE: <score>4.5</score>
MY FINAL DECISION: <decision>Reject</decision>